As measles outbreaks increase domestically & internationally, while vaccination uptake decreases in the U.S., experts discuss treatment recommendations & the immunologic consequences of measles infections in patients with rheumatic diseases.
A phase 2 study from Spiera et al. found that patients with glucocorticoid-dependent PMR taking the antibody-drug conjugate ABBV-154 had a longer time to flare compared with those taking placebo, supporting further investigation.
An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.
CPPD is notoriously difficult to diagnose due to its diverse presentations & uncertain etiology. Recent advances have helped rheumatologists better understand its risk factors, classify, diagnose & treat the condition.
Katherine Terracina, MD, & Prajakta P. Masurkar, PhD |
In addition to the impediments to consistent, high-quality care suffered by all incarcerated individuals, incarcerated patients with rheumatic disease face challenges specific to the treatment, management & monitoring of rheumatic conditions.
“Doctor, I hate to tell you this but that shelf is definitely not made of wood,” my patient gently chided me as I knocked on a plastic piece of shelving. “I know … but you get the point,” I replied with a small laugh. It’s become a habit of mine over the past few years…
In summer 2024, two phase 3 studies were released with promising findings for the treatment of patients with systemic lupus erythematosus (SLE) and those with lupus nephritis. SLE Disease Activity Dapirolizumab pegol is a novel, investigational, Fc-free anti-CD40L agent for people living with moderate to severe SLE.1 The randomized, double-blind, parallel-group PHOENYCS GO trial (N=321)…